July 2019
Volume 60, Issue 9
ARVO Annual Meeting Abstract  |   July 2019
Long-term Outcomes of Pediatric Keratoprosthesis
Author Affiliations & Notes
  • Sneha Bontu
    University of Illinois at Chicago, West Chicago, Illinois, United States
  • Priyanka Chhadva
    University of Illinois at Chicago, West Chicago, Illinois, United States
  • Jose de la Cruz
    University of Illinois at Chicago, West Chicago, Illinois, United States
  • Maria Soledad Cortina
    University of Illinois at Chicago, West Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Sneha Bontu, None; Priyanka Chhadva, None; Jose de la Cruz, None; Maria Cortina, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6318. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sneha Bontu, Priyanka Chhadva, Jose de la Cruz, Maria Soledad Cortina; Long-term Outcomes of Pediatric Keratoprosthesis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6318.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To describe the long-term outcomes of pediatric patients who underwent Boston keratoprosthesis type I implantation (Massachusetts Eye and Ear Infirmary, Boston) at a tertiary care center.

Methods : A retrospective review of patient ages 16 and younger who underwent keratoprosthesis implantation between 2008 and 2018 was completed. Eight eyes of 8 patients met inclusion criteria with a minimum follow-up of 6 months. Initial diagnosis, co-morbid ocular conditions, surgical procedures, and post-operative course were analyzed.

Results : Indications for keratoprosthesis implantation included corneal decompensation due to congenital glaucoma (3 eyes, 37.5%), Peter’s anomaly (2 eyes, 25%), aniridia (1 eye, 12.5%), cytomegalovirus (1 eye, 12.5%), and congenital hereditary endothelial dystrophy (1 eye, 12.5%). Comorbid ocular diagnoses include glaucoma (7 eyes, 87.5%) and fetal alcohol syndrome (1 eye, 12.5%). Patients had an average number of 1.5 (range 0 to 4) primary prior transplants. The mean patient age at time of keratoprosthesis transplantation was 8.86±5.26 years (range 0.8 to 15 years) and the average follow-up time was 5.6±3.2 years (range 1.6 to 9.7 years). At 1 year, 7 eyes (87.5%) retained the keratoprosthesis. Complications following keratoprosthesis implantation include retroprosthetic membrane (5 eyes, 62.5%), leakage (1 eye, 12.5%), vitreous hemorrhage (1 eye, 12.5%), extrusion (2 eyes, 25%), symblepharon (1 eye, 12.5%), and corneal melt (3 eyes, 37.5%). Subsequently, the original keratoprosthesis was removed in 5 eyes and replaced by another keratoprosthesis (2 eyes, 25%) or by a penetrating keratoplasty (3 eyes, 37.5%). Preoperative visual acuity ranged from light perception to 20/400, and vision in 3 eyes was fix and follow. At one year, vision improved to 20/150 or better in 2 eyes (25%), vision was stable in 3 eyes (37.5%), and worsened in 2 eyes (25%). At most recent follow up (mean 5.25±3.55 years, range 0.11 to 9.7 years), 2 eyes (25%) had improved vision to 20/80 or better, 2 eyes (25%) were stable at light perception, 1 eye (12.5%) decreased to light perception, whereas 3 eyes (37.5%) lost light perception.

Conclusions : While implantation of Boston type I keratoprosthesis in children is associated with more complications compared to adults, this device offers visual rehabilitation for pediatric patients with corneal decompensation and multiple prior failed transplants.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.